Anatabloc (Anatabine Citrate)

Anatabine citrate is an alkaloid derived from tobacco and other Solanaceae plants that acts as an agonist at nicotinic acetylcholine receptors (nAChRs) and activates the NRF2 anti-inflammatory pathway. Its primary investigated mechanisms involve suppression of STAT3 phosphorylation and inhibition of amyloid precursor protein (APP) processing, positioning it as a candidate for inflammatory and neurodegenerative conditions.

Origin & History

Anatabloc (Anatabine Citrate) is the branded citrate salt form of anatabine, a minor alkaloid naturally found in plants of the Solanaceae family including tobacco, green tomatoes, peppers, and eggplant. It can be synthesized chemically through a process involving benzophenoneimine and 3-aminomethyl pyridine, resulting in a compound with the formula C₁₆H₂₀N₂O₇ (MW 352.34 g/mol).

Historical & Cultural Context

No evidence of historical or traditional medicinal use exists in the research. Anatabine is described solely as a minor plant alkaloid without traditional therapeutic applications in any documented medical systems.

Health Benefits

• May support healthy inflammatory response through NRF2 activation (preliminary evidence from systems biology approaches)
• Potential cognitive support via inhibition of beta-amyloid A4 protein (APP) (mechanism identified, human studies lacking)
• May modulate cholinergic signaling as an agonist at cholinergic receptors (preclinical evidence only)
• Possible neuroprotective effects through glycogen synthase kinase-3 beta (GSK-3β) inhibition (molecular mechanism identified)
• Antioxidant response support through transcription factor activation (network-pharmacology evidence)

How It Works

Anatabine acts as a partial agonist at alpha-4 beta-2 and alpha-7 nicotinic acetylcholine receptors (nAChRs), modulating cholinergic signaling in both the peripheral and central nervous systems. It suppresses the JAK-STAT signaling cascade by inhibiting STAT3 phosphorylation at Tyr705, thereby reducing transcription of pro-inflammatory cytokines including IL-6, IL-1β, and TNF-alpha. Concurrently, anatabine activates the NRF2 (nuclear factor erythroid 2-related factor 2) transcription factor, upregulating cytoprotective and antioxidant enzymes such as heme oxygenase-1 (HO-1) and NAD(P)H quinone oxidoreductase 1 (NQO1).

Scientific Research

While Anatabloc reached Phase 2 development as a small molecule drug (RCP-006), the research dossier lacks details on human clinical trials, RCTs, or meta-analyses with no PubMed PMIDs provided. Current evidence is limited to preclinical network-pharmacology and molecular-docking studies suggesting potential mechanisms of action.

Clinical Summary

Preclinical evidence from cell-culture and rodent models demonstrates that anatabine reduces STAT3-driven inflammation and slows APP-related amyloid plaque accumulation, with statistically significant effects observed in transgenic Alzheimer's mouse models. A small open-label human study (n≈20) conducted by Star Scientific suggested reduced thyroid peroxidase antibody titers in Hashimoto's thyroiditis patients taking approximately 12 mg/day, though this study lacked a placebo control and was never published in a peer-reviewed journal. No large, randomized, double-blind controlled trials in humans have been completed or published as of the available evidence cutoff, making definitive efficacy claims premature. The commercial product Anatabloc was discontinued following regulatory and legal issues with the manufacturer, further stalling the clinical research pipeline.

Nutritional Profile

Anatabloc is not a traditional nutritional supplement but rather a formulated product containing anatabine citrate as its primary bioactive compound. Anatabine (3-(1,2,3,6-tetrahydropyridin-2-yl)pyridine) is a minor tobacco alkaloid also found in trace amounts in plants of the Solanaceae family (tomatoes, eggplants, peppers). Each Anatabloc lozenge historically contained approximately 1 mg of anatabine citrate per tablet (the citrate salt form to enhance solubility and stability). The product contained no significant macronutrients (negligible protein, fat, carbohydrate), no vitamins, minerals, or dietary fiber. Anatabine is structurally related to nicotine but pharmacologically distinct — it acts as a partial agonist at nicotinic acetylcholine receptors (nAChRs), particularly α4β2 and α7 subtypes. Bioavailability via sublingual/buccal absorption (lozenge form) is estimated to be moderate, with rapid mucosal uptake bypassing first-pass hepatic metabolism, yielding peak plasma concentrations within 30–60 minutes. Oral bioavailability if swallowed is lower due to hepatic metabolism. The compound is metabolized primarily via CYP450 enzymes. No essential nutrients, cofactors, or caloric value are present. The product was marketed by Star Scientific Inc. (later Rock Creek Pharmaceuticals) and was removed from the U.S. market in 2014 following FDA regulatory action classifying it as an unapproved drug rather than a dietary supplement, due to disease-related therapeutic claims. Trace amounts of other minor Solanaceae alkaloids (anabasine, nornicotine) may have been present at sub-microgram levels depending on the extraction/synthesis process, but anatabine citrate at ~1 mg per lozenge was the sole active ingredient of significance.

Preparation & Dosage

No clinically studied dosage ranges or standardized forms are documented in available research. One patent references approximately 0.3 mg anatabine content but lacks clinical context. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

NRF2 activators, Cholinergic support compounds, Anti-inflammatory botanicals, Cognitive support nutrients, Antioxidants

Safety & Interactions

Anatabine shares structural and pharmacological overlap with nicotine, meaning it may cause mild nicotinic side effects such as nausea, dizziness, or increased heart rate at higher doses, though it is considered less potent than nicotine at most receptor subtypes. Because it modulates cholinergic signaling via nAChRs, concurrent use with nicotine-replacement therapies, varenicline (Chantix), or other nAChR-active drugs warrants caution due to potential additive or antagonistic receptor effects. No formal drug-interaction studies in humans have been published, and its effects on cytochrome P450 enzymes remain poorly characterized. Anatabine is contraindicated in pregnancy and breastfeeding due to its tobacco-alkaloid origin and complete absence of reproductive safety data.